{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T06:53:06Z","timestamp":1772347986121,"version":"3.50.1"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,22]],"date-time":"2021-09-22T00:00:00Z","timestamp":1632268800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,9,22]],"date-time":"2021-09-22T00:00:00Z","timestamp":1632268800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100006109","name":"vedeck\u00e1 grantov\u00e1 agent\u00fara m\u0161vva\u0161 sr a sav","doi-asserted-by":"publisher","award":["VEGA 1\/0187\/17"],"award-info":[{"award-number":["VEGA 1\/0187\/17"]}],"id":[{"id":"10.13039\/501100006109","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005357","name":"agent\u00fara na podporu v\u00fdskumu a v\u00fdvoja","doi-asserted-by":"publisher","award":["APVV-17-0054"],"award-info":[{"award-number":["APVV-17-0054"]}],"id":[{"id":"10.13039\/501100005357","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s00277-021-04663-0","type":"journal-article","created":{"date-parts":[[2021,9,22]],"date-time":"2021-09-22T07:09:38Z","timestamp":1632294578000},"page":"81-89","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Ixazomib, lenalidomide, and dexamethasone combination in \u201creal-world\u201d clinical practice in patients with relapsed\/refractory multiple myeloma"],"prefix":"10.1007","volume":"101","author":[{"given":"Juraj","family":"Sokol","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2719-0540","authenticated-orcid":false,"given":"Tomas","family":"Guman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juraj","family":"Chudej","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Hlebaskova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Stecova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lubica","family":"Valekova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Kucerikova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Stasko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,9,22]]},"reference":[{"issue":"3","key":"4663_CR1","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1007\/s00277-020-04340-8","volume":"100","author":"RD Parrondo","year":"2021","unstructured":"Parrondo RD, Alegria V, Roy V, Sher T, Chanan-Khan AA, Ailawadhi S (2021) Ixazomib and lenalidomide maintenance therapy in multiple myeloma. Ann Hematol 100(3):851\u2013853. https:\/\/doi.org\/10.1007\/s00277-020-04340-8","journal-title":"Ann Hematol"},{"issue":"11","key":"4663_CR2","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.1007\/s00277-020-04234-9","volume":"99","author":"J Li","year":"2020","unstructured":"Li J, Bao L, Xia Z, Wang S, Zhou X, Ding K, Zhang W, Yang W, Li B, Fu C, Chen B, Hua L, Wang L, Luo J, Yang Y, Xu T, Wang W, Huang Y, Wu G, Liu P (2020) Ixazomib-based frontline therapy in patients with newly diagnosed multiple myeloma in real-life practice showed comparable efficacy and safety profile with those reported in clinical trial: a multi-center study. Ann Hematol 99(11):2589\u20132598. https:\/\/doi.org\/10.1007\/s00277-020-04234-9","journal-title":"Ann Hematol"},{"issue":"9983","key":"4663_CR3","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1016\/S0140-6736(14)60493-1","volume":"385","author":"C R\u00f6llig","year":"2015","unstructured":"R\u00f6llig C, Knop S, Bornh\u00e4user M (2015) Multiple myeloma. Lancet 385(9983):2197\u2013208. https:\/\/doi.org\/10.1016\/S0140-6736(14)60493-1","journal-title":"Lancet"},{"issue":"1","key":"4663_CR4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.clml.2018.08.016","volume":"19","author":"X Leleu","year":"2019","unstructured":"Leleu X, Martin TG, Einsele H, Lyons RM, Durie BGM, Iskander KS, Ailawadhi S (2019) Role of proteasome inhibitors in relapsed and\/or refractory multiple myeloma. Clin Lymphoma Myeloma Leuk 19(1):9\u201322. https:\/\/doi.org\/10.1016\/j.clml.2018.08.016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"17","key":"4663_CR5","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","volume":"374","author":"P Moreau","year":"2016","unstructured":"Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, Sandhu I, Ganly P, Baker BW, Jackson SR, Stoppa AM, Simpson DR, Gimsing P, Palumbo A, Garderet L, Cavo M, Kumar S, Touzeau C, Buadi FK, Laubach JP, Berg DT, Lin J, Di Bacco A, Hui AM, van de Velde H, Richardson PG, TOURMALINE-MM1 Study Group (2016) Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 374(17):1621\u201334. https:\/\/doi.org\/10.1056\/NEJMoa1516282","journal-title":"N Engl J Med"},{"issue":"1","key":"4663_CR6","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1097\/EDE.0000000000000564","volume":"28","author":"MA Mansournia","year":"2017","unstructured":"Mansournia MA, Higgins JP, Sterne JA, Hern\u00e1n MA (2017) Biases in randomized trials: a conversation between trialists and epidemiologists. Epidemiology 28(1):54\u201359. https:\/\/doi.org\/10.1097\/EDE.0000000000000564","journal-title":"Epidemiology"},{"issue":"1","key":"4663_CR7","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12916-019-1481-8","volume":"18","author":"SV Ramagopalan","year":"2020","unstructured":"Ramagopalan SV, Simpson A, Sammon C (2020) Can real-world data really replace randomised clinical trials? BMC Med 18(1):13. https:\/\/doi.org\/10.1186\/s12916-019-1481-8","journal-title":"BMC Med"},{"issue":"8","key":"4663_CR8","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, Munshi N, Lonial S, Blad\u00e9 J, Mateos MV, Dimopoulos M, Kastritis E, Boccadoro M, Orlowski R, Goldschmidt H, Spencer A, Hou J, Chng WJ, Usmani SZ, Zamagni E, Shimizu K, Jagannath S, Johnsen HE, Terpos E, Reiman A, Kyle RA, Sonneveld P, Richardson PG, McCarthy P, Ludwig H, Chen W, Cavo M, Harousseau JL, Lentzsch S, Hillengass J, Palumbo A, Orfao A, Rajkumar SV, Miguel JS, Avet-Loiseau H (2016) International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 17(8):e328\u2013e346. https:\/\/doi.org\/10.1016\/S1470-2045(16)30206-6","journal-title":"Lancet Oncol"},{"issue":"12","key":"4663_CR9","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kastritis E, Richardson P, Landgren O, Paiva B, Dispenzieri A, Weiss B, LeLeu X, Zweegman S, Lonial S, Rosinol L, Zamagni E, Jagannath S, Sezer O, Kristinsson SY, Caers J, Usmani SZ, Lahuerta JJ, Johnsen HE, Beksac M, Cavo M, Goldschmidt H, Terpos E, Kyle RA, Anderson KC, Durie BG, Miguel JF (2014) International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15(12):e538\u2013e548. https:\/\/doi.org\/10.1016\/S1470-2045(14)70442-5","journal-title":"Lancet Oncol"},{"issue":"15","key":"4663_CR10","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","volume":"23","author":"PR Greipp","year":"2005","unstructured":"Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blad\u00e9 J, Boccadoro M, Child JA, Avet-Loiseau H, Kyle RA, Lahuerta JJ, Ludwig H, Morgan G, Powles R, Shimizu K, Shustik C, Sonneveld P, Tosi P, Turesson I, Westin J (2005) International staging system for multiple myeloma. J Clin Oncol 23(15):3412\u20133420. https:\/\/doi.org\/10.1200\/JCO.2005.04.242","journal-title":"J Clin Oncol"},{"key":"4663_CR11","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) v4.0. Available at: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm#ctc_60. Accessed June 21, 2021"},{"issue":"5","key":"4663_CR12","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1080\/13543784.2019.1596258","volume":"28","author":"P Smolewski","year":"2019","unstructured":"Smolewski P, Rydygier D (2019) Ixazomib: an investigational drug for the treatment of lymphoproliferative disorders. Expert Opin Investig Drugs 28(5):421\u2013433. https:\/\/doi.org\/10.1080\/13543784.2019.1596258","journal-title":"Expert Opin Investig Drugs"},{"key":"4663_CR13","doi-asserted-by":"publisher","first-page":"217","DOI":"10.2147\/DDDT.S93602","volume":"10","author":"B Muz","year":"2016","unstructured":"Muz B, Ghazarian RN, Ou M, Luderer MJ, Kusdono HD, Azab AK (2016) Spotlight on ixazomib: potential in the treatment of multiple myeloma. Drug Des Devel Ther 10:217\u2013226. https:\/\/doi.org\/10.2147\/DDDT.S93602","journal-title":"Drug Des Devel Ther"},{"issue":"5","key":"4663_CR14","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1158\/0008-5472.CAN-09-2766","volume":"70","author":"E Kupperman","year":"2010","unstructured":"Kupperman E, Lee EC, Cao Y, Bannerman B, Fitzgerald M, Berger A, Yu J, Yang Y, Hales P, Bruzzese F, Liu J, Blank J, Garcia K, Tsu C, Dick L, Fleming P, Yu L, Manfredi M, Rolfe M, Bolen J (2010) Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res 70(5):1970\u20131980. https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-2766","journal-title":"Cancer Res"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-021-04663-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-021-04663-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-021-04663-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,3]],"date-time":"2022-01-03T15:07:50Z","timestamp":1641222470000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-021-04663-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,22]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["4663"],"URL":"https:\/\/doi.org\/10.1007\/s00277-021-04663-0","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,22]]},"assertion":[{"value":"21 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}